Study Overview: This research compares the effects of adding two drugs, brentuximab vedotin and nivolumab, to the standard treatment for Hodgkin lymphoma, a type of cancer. Standard therapy includes chemotherapy (using strong medicines to kill cancer cells) with or without radiation (high-energy rays to kill cancer cells). Brentuximab vedotin is a special medicine that targets certain cancer cells to kill them. Nivolumab helps the body’s immune system fight cancer. The study will see if this new combination helps patients live longer or have fewer side effects.
- Duration: Follow-up lasts up to 12 years after treatment.
- Eligibility: Patients aged 5-60 with specific Hodgkin lymphoma types.
- Participation: Involves regular check-ups and possible imaging scans.
Patients will receive either the standard therapy alone or with the new drugs. The research will compare their progress to see which group does better. This can help doctors find better ways to treat Hodgkin lymphoma in the future. Participants will undergo several medical tests and may need to provide blood samples during the study. This study helps advance cancer treatment and could benefit future patients with similar conditions.